An author shares his own story about the "pay me now or pay me later" relationship between . (Washington Post)
Three pending have the potential to reshape the authority of the federal agencies that regulate healthcare. (Association for Clinical Oncology)
The odronextamab for relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma because of slow enrollment in two confirmatory clinical trials, Regeneron announced.
Two-thirds of live in counties that have high levels of social vulnerability. (Morbidity and Mortality Weekly Report)
Results of preclinical studies suggest the combination of venetoclax (Venclexta) and 5-azacitidine (Vidaza) might have substantial anticancer . (Royal College of Surgeons in Ireland)
A may play a role in a broad range of solid tumors. (Johns Hopkins Medicine, JCO Precision Oncology)
Medexus Pharmaceuticals announced FDA approval of recombinant coagulation factor IX (Ixinity) for on-demand, prophylactic, and perioperative treatment of in patients younger than 12 years of age.
A Medicare policy for may be "undermining the purpose for which it was created." (Mount Sinai, Annals of Family Medicine)
A new guideline from the American Society of Clinical Oncology offers recommendations and information about .
News of Kate Middleton's cancer diagnosis has focused new attention on the puzzling rise in . (Time)
Bristol Myers Squibb announced that a pivotal trial of adagrasib (Krazati) in met the primary endpoint of progression-free survival.